Bradmer Announces Fourth Quarter and Full Year 2017 Financial Results

Bradmer Pharmaceuticals (TSXV:BMR.H) announced its fourth quarter and full year 2017 financial results.

As quoted in the press release:

For the three months ended December 31, 2017, the Company recorded a net loss of $74,000 or $0.004 per common share based on the weighted average outstanding shares of 19,659,726 during the three-month period, compared to a net loss of $21,000 or $0.001 per common share for the quarter ended December 31, 2016 based on the same shares outstanding.

General and administrative expenses were $75,000 in the three months ended December 31, 2017 compared to $31,000 in the same quarter of the prior year. Major expenses in 2017 consisted of consulting fees of $14,000, directors’ and officers’ liability insurance premiums of $2,000, audit fees of $2,000 and legal fees of $54,000. In 2016 major expenses consisted of consulting fees of $13,000, directors’ and officers’ liability insurance premiums of $2,000, audit fees of $2,000 and legal fees of $8,000.

Click here to read the full press release.